The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis

Bibliography

• Halloran P, Mathew T, Tomlanovich S, Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63(1):39-47
   PubMed Web of Science ®Google Scholar
• Fujihara CK, Malheiros DM, Zatz R, Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998;54(5):1510-9
   PubMed Web of Science ®Google Scholar
• Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998;31(2):213-7
   PubMed Web of Science ®Google Scholar
• Sollinger HW. Mycophenolate mofetil. Kidney Int Suppl 1995;52:S14-7
   PubMed Web of Science ®Google Scholar
• Danovitch GM. Immunosuppressive medications for renal transplantation: a multiple choice question. Kidney Int 2001;59(1):388-402
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47(2-3):85-118
   PubMed Web of Science ®Google Scholar
• Romero F, Rodriguez-Iturbe B, Parra G, Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999;55(3):945-55
   PubMed Web of Science ®Google Scholar
• Bloudickova S, Rajnoch J, Lodererova A, Mycophenolate mofetil ameliorates accelerated progressive nephropathy in rat. Kidney Blood Press Res 2006;29(1):60-6
   PubMed Web of Science ®Google Scholar
• Kramer S, Loof T, Martini S, Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril. Am J Physiol Renal Physiol 2005;289(2):F359-68
   PubMed Web of Science ®Google Scholar
• Luca ME, Paul LC, van Der Wal AM, Treatment with mycophenolate mofetil attenuates the development of Heymann nephritis. Exp Nephrol 2000;8(2):77-83
   PubMedGoogle Scholar
• Utimura R, Fujihara CK, Mattar AL, Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003;63(1):209-16
   PubMed Web of Science ®Google Scholar
• Wu YG, Lin H, Qi XM, Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. Int Immunopharmacol 2006;6(3):445-53
   PubMed Web of Science ®Google Scholar
• Wu Y, Dong J, Yuan L, Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy. Cytokine 2008;44(1):85-91
   PubMed Web of Science ®Google Scholar
• Patari-Sampo A, Ihalmo P, Holthofer H. Molecular basis of the glomerular filtration: nephrin and the emerging protein complex at the podocyte slit diaphragm. Ann Med 2006;38(7):483-92
   PubMed Web of Science ®Google Scholar
• Nakhoul F, Ramadan R, Khankin E, Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies. Am J Physiol Renal Physiol 2005;289(4):F880-90
   PubMed Web of Science ®Google Scholar
• Badid C, Vincent M, McGregor B, Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000;58(1):51-61
   PubMed Web of Science ®Google Scholar
• Dubus I, Vendrely B, Christophe I, Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 2002;62(3):857-67
   PubMed Web of Science ®Google Scholar
• Bargman JM. Management of minimal lesion glomerulonephritis: evidence-based recommendations. Kidney Int Suppl 1999;70:S3-16
   PubMed Web of Science ®Google Scholar
• Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001;16(3):271-82
   PubMed Web of Science ®Google Scholar
• Meyrier A, Noel LH, Auriche P, Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 1994;45(5):1446-56
   PubMed Web of Science ®Google Scholar
• Day CJ, Cockwell P, Lipkin GW, Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002;17(11):2011-3
   PubMed Web of Science ®Google Scholar
• Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 2004;19(1):101-4
   PubMed Web of Science ®Google Scholar
• Mendizabal S, Zamora I, Berbel O, Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 2005;20(7):914-9
   PubMed Web of Science ®Google Scholar
• Choi MJ, Eustace JA, Gimenez LF, Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61(3):1098-114
   PubMed Web of Science ®Google Scholar
• Pesavento TE, Bay WH, Agarwal G, Mycophenolate therapy in frequently relapsing minimal change disease that has failed cyclophosphamide therapy. Am J Kidney Dis 2004;43(3):e3-6
   PubMed Web of Science ®Google Scholar
• Waldman M, Crew RJ, Valeri A, Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007;2(3):445-53
   PubMed Web of Science ®Google Scholar
• Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 2008;23(11):2013-20
   PubMed Web of Science ®Google Scholar
• Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002;62(6):2301-10
   PubMed Web of Science ®Google Scholar
• Chun MJ, Korbet SM, Schwartz MM, Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15(8):2169-77
   PubMed Web of Science ®Google Scholar
• Burgess E. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int Suppl 1999;70:S26-32
   PubMed Web of Science ®Google Scholar
• Cameron JS. Focal segmental glomerulosclerosis in adults. Nephrol Dial Transplant 2003;18 (Suppl 6):vi45-51
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Rizzoni G, Edefonti A, A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43(6):1377-84
   PubMed Web of Science ®Google Scholar
• Cattran DC. Cyclosporine in the treatment of idiopathic focal segmental glomerulosclerosis. Semin Nephrol 2003;23(2):234-41
   PubMed Web of Science ®Google Scholar
• Goumenos DS, Tsagalis G, El Nahas AM, Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron Clin Pract 2006;104(2):c75-82
   PubMed Web of Science ®Google Scholar
• Cattran DC, Wang MM, Appel G, Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004;62(6):405-11
   PubMed Web of Science ®Google Scholar
• Segarra A, Amoedo ML, Martinez Garcia JM, Efficacy and safety of ‘rescue therapy’ with mycophenolate mofetil in resistant primary glomerulonephritis – a multicenter study. Nephrol Dial Transplant 2007;22(5):1351-60
   PubMed Web of Science ®Google Scholar
• Montané B, Abitbol C, Chandar J, Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003;18(8):772-7
   PubMed Web of Science ®Google Scholar
• Dimkovic N, Jovanovic D, Kovacevic Z, Mycophenolate mofetil in high-risk patients with primary glomerulonephritis: results of a 1-year prospective study. Nephron Clin Pract 2009;111(3):c189-96
   PubMed Web of Science ®Google Scholar
• Senthil Nayagam L, Ganguli A, Rathi M, Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008;23(6):1926-30
   PubMed Web of Science ®Google Scholar
• Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 2008;3(3):905-19
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Zucchelli P, Passerini P, A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989;320(1):8-13
   PubMed Web of Science ®Google Scholar
• Jha V, Ganguli A, Saha TK, A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007;18(6):1899-904
   PubMed Web of Science ®Google Scholar
• Goumenos DS, Kalliakmani P, Tsakas S, The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol 2004;61(1):17-24
   PubMed Web of Science ®Google Scholar
• Alexopoulos E, Papagianni A, Tsamelashvili M, Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 2006;21(11):3127-32
   PubMed Web of Science ®Google Scholar
• Miller G, Zimmerman R III, Radhakrishnan J, Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000;36(2):250-6
   PubMed Web of Science ®Google Scholar
• Polenakovic M, Grcevska L, Dzikova S. Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant 2003;18(6):1233-4
   PubMed Web of Science ®Google Scholar
• Ballarin J, Poveda R, Ara J, Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant 2007;22(11):3196-201
   PubMed Web of Science ®Google Scholar
• Branten AJ, du Buf-Vereijken PW, Vervloet M, Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007;50(2):248-56
   PubMed Web of Science ®Google Scholar
• Dussol B, Morange S, Burtey S, Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis 2008;52(4):699-705
   PubMed Web of Science ®Google Scholar
• Chan TM, Lin AW, Tang SC, Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 2007;12(6):576-81
   PubMed Web of Science ®Google Scholar
• D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987;64(245):709-27
   PubMedGoogle Scholar
• Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002;347(10):738-48
   PubMed Web of Science ®Google Scholar
• Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005;16(7):2088-97
   PubMed Web of Science ®Google Scholar
• D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004;24(3):179-96
   PubMed Web of Science ®Google Scholar
• Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005;18(5):503-12
   PubMed Web of Science ®Google Scholar
• Chen X, Chen P, Cai G, A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi 2002;82(12):796-801
   PubMedGoogle Scholar
• Maes BD, Oyen R, Claes K, Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004;65(5):1842-9
   PubMed Web of Science ®Google Scholar
• Frisch G, Lin J, Rosenstock J, Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005;20(10):2139-45
   PubMed Web of Science ®Google Scholar
• Tang S, Leung JC, Chan LY, Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005;68(2):802-12
   PubMed Web of Science ®Google Scholar
• Xu G, Tu W, Jiang D, Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis. Am J Nephrol 2009;29(5):362-7
   PubMed Web of Science ®Google Scholar
• Rasche FM, Keller F, von Muller L, Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy. J Nephrol 2006;19(4):465-72
   PubMed Web of Science ®Google Scholar
• Tan CH, Loh PT, Yang WS, Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review. Singapore Med J 2008;49(10):780-5
   PubMed Web of Science ®Google Scholar
• Davies NM, Grinyo J, Heading R, Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 2007;22(9):2440-8
   PubMed Web of Science ®Google Scholar
• Selbst MK, Ahrens WA, Robert ME, Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Mod Pathol 2009;22(6):737-43
   PubMed Web of Science ®Google Scholar
• Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998;65(11):1450-4
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20(5):1103-12
   PubMed Web of Science ®Google Scholar
• Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997;175(4):901-4
   PubMed Web of Science ®Google Scholar
• Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002;35(1):53-61
   PubMed Web of Science ®Google Scholar
• Lv J, Zhang H, Cui Z, Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol Dial Transplant 2008;23(9):2868-72
   PubMed Web of Science ®Google Scholar
• O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25(10):1186-91
   PubMed Web of Science ®Google Scholar
• Robson R, Cecka JM, Opelz G, Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005;5(12):2954-60
   PubMed Web of Science ®Google Scholar
• Briggs WA, Choi MJ, Scheel PJ Jr. Follow-up on mycophenolate treatment of glomerular disease. Am J Kidney Dis 1998;31(5):898-9
   PubMed Web of Science ®Google Scholar